BUZZ-Street View: CVS Health to thrive with Aetna stabilization

Reuters
02-13
BUZZ-Street View: CVS Health to thrive with Aetna stabilization

** Healthcare conglomerate CVS Health CVS.N beat Wall Street estimates for fourth-quarter profit on Wednesday and provided an annual forecast that largely met expectations

** Results and forecast hinted at an improvement in performance in its first full quarter under new CEO David Joyner

** Median PT of 29 brokerages covering CVS is $65 - according to data compiled by LSEG

DOSE OF STABILITY

** Leerink Partners ("outperform", PT: $75) sees CVS stabilizing, particularly with health insurance unit Aetna

** Jefferies ("buy", PT: $74) sees CVS' stabilization of Aetna leading to early success in 2025 with low downside risk, and projected further EPS and increase in stock price if elevated use of medical services by its members subsides

** Morgan Stanley ("overweight", PT: $68) sees potential earnings upside for CVS in 2025 from improved cost trends and Medicare Advantage $(MA)$ margins

** Evercore ISI ("outperform", PT: $80) sees CVS balanced, with realistic expectations for Medicaid rate and MA operating margin improvements, and also highlighted continued underlying improvements in its insurance unit

(Reporting by Rashika Singh in Bengaluru)

((rashika.singh@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10